Urgent

Serious infection on biologic and DMARD therapy

Immunosuppressed rheumatology patient · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Patients on biologic and conventional DMARD therapy are at increased risk of serious and opportunistic infection, which may present atypically with blunted signs. Any significant infection warrants prompt broad assessment, consideration of opportunistic pathogens and temporary withholding of immunosuppression.

Red flags

  • Features of sepsis or septic shock
  • Hypoxaemia with diffuse infiltrates (PJP)
  • Fever, night sweats and weight loss on anti-TNF (TB)
  • Neutropenia on DMARD therapy
  • Vesicular rash / dermatomal zoster with dissemination

Assessment

Differential diagnosis

  • Bacterial sepsis (common organisms)
  • Tuberculosis reactivation (anti-TNF)
  • Pneumocystis jirovecii pneumonia
  • Invasive fungal infection
  • Viral reactivation (hepatitis B, VZV, CMV)
  • Disease flare mimicking infection

Investigations

  • FBC, CRP, blood cultures, lactate and septic screen
  • Chest radiograph / CT and site-specific imaging
  • TB testing (IGRA, sputum) if anti-TNF and suggestive features
  • PJP work-up (beta-D-glucan, induced sputum/BAL) if hypoxaemic
  • Hepatitis B/C, HIV and viral PCRs as indicated
  • Review of current immunosuppressant regimen and recent changes

Management

  • Assess for sepsis using a structured tool and resuscitate with the sepsis six
  • Take cultures and start empirical broad-spectrum antibiotics early for suspected sepsis
  • Withhold biologic and DMARD therapy during significant infection
  • Actively consider opportunistic infections given the specific agent (TB with anti-TNF, PJP with combined immunosuppression)
  • Give stress-dose steroid cover if on long-term glucocorticoids and septic
  • Check for drug-induced neutropenia contributing to infection
  • Liaise with rheumatology before restarting immunosuppression and with microbiology for targeted therapy
  • Update vaccination and consider prophylaxis (co-trimoxazole, antivirals) for future immunosuppression

Drugs & doses

Piperacillin-tazobactam — 4.5 g IV QDS empirically for undifferentiated sepsis
Co-trimoxazole — 120 mg/kg/day IV in divided doses for confirmed/suspected PJP
Hydrocortisone — 100 mg IV then 50 mg QDS for stress cover if on long-term steroids and septic
Aciclovir — 10 mg/kg IV TDS for disseminated/severe VZV or HSV
Standard quadruple anti-tuberculous therapy if TB reactivation confirmed (specialist-led)

Disposition

Admit for IV antibiotics and opportunistic infection work-up; hold immunosuppression and involve rheumatology/microbiology.

Complications & pitfalls

  • Septic shock and multi-organ failure
  • Disseminated tuberculosis
  • Severe PJP with respiratory failure
  • Hepatitis B reactivation and liver failure
  • Delayed recovery from withholding disease therapy

Exam pearls

  • Immunosuppression blunts fever and inflammatory signs - maintain a low threshold for serious infection
  • Always consider TB reactivation in patients on TNF inhibitors
  • Withhold (do not necessarily stop permanently) biologics during active infection and restart after recovery with rheumatology
  • Check TB screening and hepatitis status before, and prophylaxis during, biologic therapy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.